216
Views
1
CrossRef citations to date
0
Altmetric
Articles

Language proficiency and biologics access: a population study of psoriasis patients in the United States

ORCID Icon, , , , & ORCID Icon
Pages 1413-1417 | Received 28 Jul 2020, Accepted 28 Aug 2020, Published online: 14 Sep 2020
 

Abstract

Background

Language proficiency plays an important role in healthcare choices and access. Differences in access to biologic medications exist, but it is unknown how much English proficiency influences access in US psoriasis patients.

Objective

To compare biologic medication use for psoriasis patients with differing English proficiency levels.

Methods

Population study of US psoriasis patients using the 2013–2017 Medical Expenditure Survey.

Results

Among a total of 4,470,820 US psoriasis patients (weighted), 4,028,119 (90.1%) had perfect English proficiency, and 442,700 (9.9%) had less than perfect English proficiency. Among the total population, 422,523 (9.5%) had access to biologics. Among those who received biologics, 411,411 (97.4%) of those had perfect English proficiency, and 11,112 (2.6%) of those had less than perfect English proficiency. Multivariate logistic regression found that patients with less than perfect English proficiency were significantly less likely to have access to biologics [OR 0.015 (95% CI: 0.001–0.179); p = .002], after adjusting for insurance status, income, education, healthcare utilization, and other sociodemographic and clinical factors.

Limitations

Psoriasis disease severity not specified.

Conclusions

Psoriasis patients with low English proficiency are significantly less likely to receive biologics than those with high English proficiency. Those with higher English proficiency are 61 times more likely to access biologics.

Disclosure statement

Dr. Armstrong has served as an investigator and/or consultant to Abbvie, BMS, Dermavant, Dermira, Eli Lilly, Janssen, Leo Pharma, Kyowa Hakko Kirin, Modernizing Medicine, Novartis, Ortho Dermatologics, Regeneron, Sanofi, Sun Pharma, and UCB.

Availability of data statement

The datasets generated during and/or analyzed during the current study are available in the AHRQ RDC repository, https://meps.ahrq.gov/mepsweb/data_stats/onsite_datacenter.jsp

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.